About N-Power Medicine

N-Power Medicine aims to establish a new paradigm in drug development by reinventing the ‘how’ and transforming clinical trials through better integration with clinical practice, ensuring broader participation by physicians and patients. We are building an exceptional multi-disciplinary team with diverse expertise spanning healthcare, engineering, technology, and regulatory, and with people who share our core value of Empowering Community through generosity, curiosity, and humility. We are working with urgency to bring better therapies to patients faster.

Position Overview

The Senior Director, Clinical Research Operations is responsible for scaling and leading the operating model that allows N-Power to run clinical research efficiently across a growing network of oncology practices. This newly created role will be accountable for the clinical research staff organization embedded at network practices and the clinical operations function responsible for study start-up, regulatory, and trial conduct.

The Senior Director will set the organizational design, operating model, and performance standards that drive scalability, staffing, capacity planning, and training infrastructure.

This is a remote role.

Role Objectives and Responsibilities

Operating Model, Performance Management and Research Operations Scale-up

Responsible for executing a long-term operating model for clinical research across the N-Power network, anticipating the organizational, process, and resourcing needs of a rapidly expanding network
Develop a scalable site activation and research integration approach that allows new practices to be brought onto the network quickly, consistently, and cost-effectively
Identify standardization, centralization, and technology enablement to reduce per-site operational burden and improve productivity.
Own the performance and reporting framework that gives executive leadership clear visibility into network research performance, risks, and investment needs.

Organizational Leadership & Execution

Build and lead a multi-layer organization spanning the distributed clinical research field team and clinical operations
Design the organizational structure, roles, career paths, and management cadence needed to sustain quality and engagement as the team scales across geographies
Establish the training, onboarding, and development infrastructure that allows the function to grow while maintaining consistent standards of practice
Build a culture of accountability, continuous improvement, and mission alignment, ensuring onsite teams are equipped to represent N-Power's value proposition to practices and physicians
Drive improvements in operational efficiency and unit economics as the network grows
Serve as an escalation point for site-level relationship risks and support rollout of new initiatives or workflow changes across the network
Partner closely with Network Operations leadership and other cross-functional teams to align CRS and Clinical Operations priorities with broader network strategy

Perform additional duties and responsibilities as required.

Education, Experience, Behavioral Competencies, & Skills

10+ years of experience in clinical research operations, including direct, hands-on oncology clinical trial experience
Proven success leading and managing a multi-layer, distributed, research workforce at scale
Strong understanding of oncology practice workflows, including academic/community research and practice administration
Demonstrated ability to build repeatable playbooks, SOPs, and processes as teams and programs grow
Track record of driving operational efficiency through process standardization, centralization, and technology adoption
Experience building staffing models, capacity plans, and KPI/reporting frameworks
Experience designing training and development infrastructure for a distributed clinical workforce
Bachelor’s degree or equivalent professional experience
Exceptional written and verbal communication skills, with the ability to engage and influence senior stakeholders, clinical teams, and technical experts alike
Collaborative, hands-on leader who thrives in dynamic environments; generous, curious, and humble

Preferred

Familiarity with CTMS, EDC, or similar clinical trial systems as they relate to site-level workflow

Travel Requirements

Travel expected on an as-needed basis to support regional teams. Up to 25%

Pay Information

The expected salary range for this position is $215K-230K. Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors permitted by law. N-Power Medicine (NPM) offers equity at hire as well as a discretionary annual bonus which may be available based on Company performance. This position is eligible for company benefits.

More About Us

We are a mission-driven, well-funded, rapidly growing company, eager to attract passionate professionals offering a highly attractive compensation package with a balanced and flexible work environment, competitive industry benefits as well as a 401K plan.

We are an Equal Opportunity Employer and value diversity at our company. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, or other applicable legally protected characteristics.

Applicants must be currently authorized to work in the U.S. on a full-time basis. The Company will not sponsor applicants for work visas.

Please note that state-specific background checks and screenings may be required for this role. Employment is contingent upon successfully passing all applicable screenings.

Notice on fraudulent job offers: Only positions posted on the https://npowercareers.multiscreensite.com/ site are legitimate. Please be mindful of recruitment fraud and job scams.

About the company

N-Power Medicine focuses on oncology-related drug development services. It accelerates the creation of cancer therapies by partnering with pharmaceutical companies and research institutions, leveraging advanced technologies and innovative methods to shorten development timelines and bring effective treatments to patients faster. The company’s services are delivered through collaborations, earning revenue from service fees, research grants, and potential licensing of its proprietary technologies. Compared with competitors, it emphasizes specialized oncology expertise, active partnerships, and a workflow that combines research services with opportunities for licensing, aiming to streamline development rather than just offer generic research support. The goal is to improve patient outcomes by speeding up the availability of effective cancer treatments.

Company Size

51-200

Company Stage

Series B

Total Funding

$32M

Headquarters

Redwood City, California

Founded

2021

Get referred to N-Power Medicine

See people who can refer or advise you

Simplify's Take

What believers are saying

September 1, 2026 Series B raised $32 million from Labcorp Venture Fund.
N-Power said ProECA is live at 40-plus sites and supports pharma programs.
AdventHealth partnered in January 2026; colorectal and prostate ProECA launches follow.

What critics are saying

If Merck, Labcorp, or other pharma partners stall, revenue concentration bites quickly.
FDA and oncology buyers can reject external controls, undermining ProECA's core thesis.
If ProECA gains no regulatory traction, N-Power's business model collapses.

What makes N-Power Medicine unique

N-Power's ProECA platform runs prospective external controls inside routine community oncology care.
Syapse added 1,000-plus oncologists and community health-system distribution in January 2025.
Its always-on network targets faster trials without replacing community treatment workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan
Wellness Program
Flexible Work Hours
Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Yahoo Finance

Oct 8th, 2026

N-Power Medicine partners with NYCBS to scale prospective external control arms in community oncology

N-Power Medicine and New York Cancer & Blood Specialists have partnered to scale Prospective External Control Arms (ProECA) in community oncology. The collaboration combines N-Power's ProECA platform with NYCBS's research programme to accelerate oncology drug development. N-Power's ProECA platform creates standalone, protocol-driven control arms by collecting trial-grade data on patients receiving standard-of-care therapy. This approach can reduce the need for randomisation in clinical trials and accelerate the development of new cancer therapies. NYCBS will join the N-Power Network and offer ProECA programmes to its patients, starting with non-small cell lung cancer. The practice brings over 90 medical oncologists at more than 30 locations across New York. The N-Power Network now spans over 50 community oncology sites across multiple large health systems.

The Mirror Democrat and Savanna Times-Journal

Oct 8th, 2026

N-Power Medicine and New York Cancer & Blood Specialists partner to scale Prospective External Control Arms (ProECA) in community oncology.

N-Power Medicine and New York Cancer & Blood Specialists partner to scale Prospective External Control Arms (ProECA) in community oncology. * 1 hr ago N-Power Medicine, a company transforming oncology drug development, and New York Cancer & Blood Specialists (NYCBS), one of the nation's largest independent community oncology practices and a longtime leader in clinical research, today announced a strategic partnership to accelerate the generation of N-Power's Prospective External Control Arms (ProECAs). This novel approach is designed to reduce the size of oncology clinical trials and bring new therapies to patients years sooner. As part of the partnership, NYCBS will participate in the N-Power Network and offer ProECA programs to its patients, beginning in non-small cell lung cancer (NSCLC). N-Power's ProECA platform builds standalone, protocol-driven control arms by collecting trial-grade data on patients receiving standard-of-care therapy. Unlike retrospective approaches that rely on data generated without a standardized framework, ProECAs are designed from the outset with protocolized data collection and imaging-based endpoints aligned with clinical trial standards. ProECAs can reduce the need for randomization, improve decision-making in early development and advance promising molecules into late-phase trials. NYCBS brings more than 90 medical oncologists at over 30 locations across New York, adding a large, diverse patient population to the N-Power Network and providing its patients with broader access to clinical research as part of the care they already receive. The N-Power Network spans more than 50 community oncology sites across multiple large health systems. Pharmaceutical and biotech partners already use N-Power's NSCLC ProECA to accelerate early development and Phase 4 programs, and N-Power plans to expand across major cancer indications, with a colorectal program launching later this year. "Clinical research has long been central to how we care for patients at NYCBS, and this partnership extends that commitment across our entire practice," said Justas Lauzadis, PhD, chief research officer of New York Cancer & Blood Specialists. "By building trial-grade data collection into everyday care, we give more patients the opportunity to contribute to research without adding burden for them or our physicians. Adopting prospective external control arms enhances our research program for our patients living with NSCLC, and we look forward to expanding ProECA to additional indications." "We are thrilled to welcome New York Cancer & Blood Specialists to the N-Power Network," said Mark Lee, MD, PhD, co-founder and chief executive officer of N-Power Medicine. "NYCBS is one of the most respected independent oncology practices in the country, and its scale, research experience and deep roots in New York communities make it an ideal partner for ProECA. Together, we can generate the high-quality evidence needed for faster, smarter drug development while bringing more research opportunities to thousands of patients close to home." About N-Power Medicine N-Power Medicine has built a national network of community oncology centers, creating the first "always-on" Prospective External Control Arm (ProECA) platform that enables drug developers to reduce or replace randomized control arms and run faster, smaller, more efficient clinical trials, while simultaneously expanding access to clinical research and innovation for physicians and patients in the communities where they live. About New York Cancer & Blood Specialists New York Cancer & Blood Specialists is a leading oncology practice dedicated to providing world-class, patient-centered, and affordable care to individuals with cancer and blood disorders throughout New York State. With locations across Long Island, New York City, and the Hudson Valley, its mission is to bring world-class cancer care close to home, where patients can heal with the support of family and community. Media gallery

San Francisco Biotechnology Network

Sep 1st, 2026

N-Power Medicine closes $32 million Series B financing to expand its community oncology network and accelerate proeca adoption.

N-Power Medicine closes $32 million Series B financing to expand its community oncology network and accelerate proeca adoption. REDWOOD CITY, Calif.-(BUSINESS WIRE)-N-Power Medicine, a company reinventing oncology drug development and community cancer patient care, today announced the close of a $32 million Series B financing round to fuel the company's next phase of growth - expanding its community oncology network, deepening pharma partnerships and continued investment in product development. The round includes new strategic investor Labcorp Venture Fund, along with continued participation from Merck Global Health I Click here to view original post Discover more Ordering Science Kits Ordering DNA Kits

Associated Press

Sep 1st, 2026

N-Power Medicine raises $32M Series B to expand oncology network and ProECA platform

N-Power Medicine, a Redwood City-based oncology company, has closed a $32 million Series B funding round. The financing was led by new investor Labcorp Venture Fund, with participation from existing backers Merck Global Health Innovation Fund, Innovatus Capital Partners, and another biotech investor. The company operates a community oncology research network and develops Prospective External Control Arms (ProECA), which enable smaller, faster clinical trials with reduced patient enrollment requirements. Its platform allows pharmaceutical companies to run more efficient trials whilst expanding research access in community care settings. N-Power's first ProECA programme focuses on non-small cell lung cancer and is operational across more than 40 sites. The company plans to launch ProECA programmes in colorectal cancer and prostate cancer later this year. The funds will support network expansion and deeper pharmaceutical partnerships.

American Cancer Center

Aug 20th, 2026

Highlights from volume 41, number 4 Oncology Issues.

Highlights from volume 41, number 4 Oncology Issues. August 20, 2026 From precision medicine to psychosocial care to navigation for a diverse population, the latest issue Oncology Issues brings insights into not just institutional and administrative barriers to treatment, but areas of care that directly impact the lived experience of those navigating the cancer care continuum. The newest issue of Oncology Issues offers innovative tools, workflows, and patient-centered treatment methodologies designed to improve accessibility, equity, and the patient experience. From precision medicine to psychosocial care to navigation for a diverse population, this issue brings insights into not just institutional and administrative barriers to treatment, but areas of care that directly impact the lived experience of those navigating the cancer care continuum. Read on for a preview of the important work being done in multidisciplinary care teams across ACCC's membership in the latest Oncology Issues. Unlocking precision oncology through smarter data. Precision oncology is transforming cancer care, but fragmented data, evolving knowledge, and complex workflows create significant challenges for community cancer centers. Bayhealth - Delaware's second largest health system - and N-Power Medicine - an oncology research network, data, technology, and service provider - teamed up to develop a sustainable precision oncology and research program. This article explores how community oncology programs can collaborate with technology and research companies to expand diagnostic and treatment offerings. Learn how Bayhealth and N-Power Medicine have leveraged data integration, technology, and multidisciplinary expertise to harmonize clinical and molecular information and build a more connected approach to a precision oncology program. Implementing Collaborative behavioral health care in community oncology. Clinical advances such as molecular diagnostics and immunotherapy have made cancer care increasingly precise, but too often, the psychosocial effects of treatment do not receive the same rigorous attention. In the Collaborative Care Model, behavioral health is integrated into medical care rather than operating as a separate referral pathway, ensuring mental health is not an afterthought. Building team-based care in community oncology. Amid growing complexity in cancer treatments and patient needs, building a cohesive, multidisciplinary care team is more important than ever. For Cancer Care Associates of York, a team-based approach to care coordination has proven vital in improving staff communication, combatting clinician burnout, and enhancing patient outcomes. Advancing whole-person Cancer Care with transcranial magnetic stimulation. Depression in oncology is not only distressing to patients, but also a clinically significant concern, associated with greater symptom burden, poorer treatment adherence, and reduced quality of life. While antidepressants and other systemic medications are a common solution, clinicians and patients may prefer to avoid additional drugs due to adverse effects, drug-drug interactions, or patient preference. This article explores the potential of transcranial magnetic stimulation (TMS), a noninvasive intervention for depression that offers a nonpharmacologic treatment option and may help overcome some of the barriers associated with traditional antidepressants. Learn more about how TMS works, safety considerations, and which groups of patients may be good candidates for this treatment. Community, culture, and care: transforming oncology Services through Native Health Navigation. During the COVID-19 pandemic, CHRISTUS St Vincent Regional Medical Center in New Mexico identified significant gaps in the healthcare system for American Indian patients, particularly when being referred from the Indian Health Service for complex cases. In response, the center created a Native Health Navigation Program, run by and for American Indians, to support the logistical and cultural transition between healthcare providers. Through patient support and provider education, this program offers culturally responsive care that helps patients better navigate the healthcare system and access clinical trials. Read the full article to understand how this cancer program approaches navigation for its unique community to ensure patients feel heard, respected, and supported. The future of Cancer Care is predictive - and it's here. For patients with early-stage Hodgkin lymphoma, high cure rates have brought a new challenge: how to balance effective treatment with the long-term consequences of therapy. Through a global collaboration involving RWJBarnabas Health/Rutgers Cancer Institute, Tufts Medical Center, and the University of Manchester, researchers developed the Early-Stage cHL International Prognostic Index, the first validated risk prediction model for adults diagnosed with early-stage Hodgkin lymphoma. For this article, Oncology Issues interviewed Andrew M. Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Institute and Chief Physician Officer at the Jack & Cheryl Morris Cancer Center, about how this partnership is improving patient care by quantifying risk at the individual level, rather than applying a one-size-fits-all approach to treatment. Dr. Evens describes the data-driven tool's ability to bring greater precision to risk assessment, treatment decisions, and patient conversations, as well as its accessibility as a free online resource. University of Chicago's path to operationalizing decentralized phase 1 trials across a regional network. There is a common and deeply rooted assumption in oncology that early-phase clinical trials must be limited to academic centers to remain safe. University of Chicago Medicine challenges that belief through its commitment to offering decentralized clinical trials (DCTs), which bring some or all elements of clinical research closer to patients. This case study explores the program's approach, a decade in the making, to offering phase 1 DCTs across a regional network, demonstrating how decentralization can expand access, engage diverse populations, and preserve safety. Read about the lessons learned at University of Chicago Medicine regarding infrastructure, financing, and patient experience that can be applied to clinical research across cancer programs. Beyond the features. In addition to the feature articles, this issue of Oncology Issues offers: * Columns from Editor-in-Chief Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC, and 2025-2026 ACCC President Una Hopkins, DNP, MSN, BSN, FNP-BC, NE-BC, FACCC, RN * An overview of how new Medicaid work requirements impact eligibility * A guide to the appropriate use of modifiers in oncology coding * Insights from the author of Tiny Scrubs, Big Dreams, a children's book inspiring future healthcare leaders * A spotlight on ACCC program member University of Wisconsin Carbone Cancer Center in Madison, Wisconsin. Dive into the full issue to learn from colleagues across the country and put their insights into practice.

N-Power Medicine

Senior Director - Clinical Research Operations

About the job